Contact   Sitemap   Disclaimer
Press Releases
Medivation Fact Sheet Corporate
Fact Sheet
 

= Add Release to Briefcase
All Releases
View Summary Medivation Completes Enrollment in Confirmatory, Pivotal Phase 3 'CONNECTION' Trial of Dimebon in Patients With Alzheimer's Disease
Jun 11, 2009
PDF 10.7 KB Add to Briefcase
View Summary Medivation to Present at 8th Annual Needham Life Sciences Conference
Jun 4, 2009
PDF 7.7 KB Add to Briefcase
View Summary Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients
Jun 2, 2009
PDF 12.0 KB Add to Briefcase
View Summary Medivation Announces Pricing of Public Offering
May 27, 2009
PDF 7.7 KB Add to Briefcase
View Summary Medivation Announces Offering of 2,750,000 Shares of Common Stock
May 26, 2009
PDF 7.7 KB Add to Briefcase
View Summary Medivation Announces Upcoming Presentation of New MDV3100 Data in Patients With Advanced Prostate Cancer at 45th American Society of Clinical Oncology Annual Meeting
May 21, 2009
PDF 9.3 KB Add to Briefcase
View Summary Medivation to Present at the Leerink Swann Novel Cancer Therapeutics Roundtable Conference
May 13, 2009
PDF 7.7 KB Add to Briefcase
View Summary Medivation Reports First Quarter 2009 Financial Results and Provides Corporate Update
May 11, 2009
PDF 16.8 KB Add to Briefcase
View Summary Medivation Announces First Quarter 2009 Financial Results Teleconference and Webcast on May 11, 2009
May 4, 2009
PDF 7.8 KB Add to Briefcase
  61st American Academy of Neurology (AAN) Annual Meeting Poster Session VIII
Apr 30, 2009
PDF 82.8 KB Add to Briefcase
  61st American Academy of Neurology (AAN) Annual Meeting Poster Session VI
Apr 30, 2009
PDF 69.0 KB Add to Briefcase
View Summary Medivation Announces Upcoming Scientific Presentations at Medical Conferences
Apr 23, 2009
PDF 10.0 KB Add to Briefcase
View Summary Pfizer and Medivation Initiate Phase 3 Trial of Dimebon Added to Donepezil in Patients with Alzheimer's Disease
Apr 15, 2009
PDF 12.0 KB Add to Briefcase
View Summary Medivation Announces Publication in Science Describing MDV3100's Novel and Potent Anti-Androgen Properties
Apr 7, 2009
PDF 12.5 KB Add to Briefcase
View Summary Medivation Receives FDA Permission to Initiate Phase 3 Trial of MDV3100 in Castration-Resistant Prostate Cancer
Mar 18, 2009
PDF 10.7 KB Add to Briefcase
View Summary Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update
Mar 16, 2009
PDF 18.2 KB Add to Briefcase
View Summary Medivation Announces Fourth Quarter and Year-End 2008 Teleconference and Webcast on March 16, 2009
Mar 9, 2009
PDF 7.9 KB Add to Briefcase
  Poster Presentation at ASCO 2009 Genitourinary Cancers Symposium
Feb 27, 2009
PDF 373.5 KB Add to Briefcase
View Summary Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
Feb 25, 2009
PDF 13.0 KB Add to Briefcase
View Summary Medivation to Host Conference Call and Slide Presentation at 4:30 p.m. EST Wednesday, February 25, to Discuss New MDV3100 Efficacy and Safety Data From Trial in Castration-Resistant Prostate Cancer Patients
Feb 24, 2009
PDF 8.4 KB Add to Briefcase
Showing 1-20 of 125 releases Page: 1 2 3 4 5 6 7  See Next 20

The press releases may contain historical information and may no longer be accurate. Medivation disclaims any responsibility to update such information.

Shareholder Tools

  Briefcase
  Download Library
  Email Alerts
  RSS News Feeds

Media Contacts

Amanda Mason
WeissComm Partners
1251 6th Ave.
Suite 3500
New York, NY 10020
Phone: 212-301-7221
Fax: 212-867-3249

For a high resolution copy of our logo (eps file), click here.

Medivation Homepage